Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 174 participants.

Also called NCT02552238

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 174 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02552238
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02552238. Allocation not applicable; no masking; primary purpose diagnostic. Start 2015-10-12 (actual); primary completion 2017-06-22 (actual). Results posted on 2020-08-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
Intervention (Drug)
Lumason
Lead sponsor
Bracco Diagnostics, Inc (class: industry)

Record details

Record id
cardio:ct-nct02552238
Content hash
1105c98fd2c7c85b07da905be69e7a7f04df93a28674313d4e3a4adbd7229d49